Articles tagged with Lung Cancer
Researchers have discovered that lung cancer tumors alter the odor of bodily fluids, allowing for early detection through trained animal sensors and chemical analysis. The findings hold promise for improving diagnostic and prognostic approaches to lung cancer treatment.
Scientists found that repeated exposure to tobacco smoke made lung cancer worse by causing inflammation in the lungs. The study provided definitive evidence for the role of lung inflammation in promoting lung cancer growth and suggested using anti-inflammatory agents to prevent or slow lung cancer progression.
Researchers identify a potential molecular mechanism by which NNK promotes lung tumor formation and development through DNMT1 accumulation. Accumulation of DNMT1 in lung adenomas from NNK-treated mice and tumors from lung cancer patients correlated with poor prognosis, suggesting an important link between tobacco smoking and lung cancer.
A team of researchers has identified a potential mechanism by which the tobacco-specific carcinogen NNK promotes lung tumor formation. They also found that statins may protect against invasive pneumococcal infections in children with sickle cell disease. Additionally, a new oncogenic protein called Nlp was discovered to be expressed at...
Researchers found that identifying patients with a small number of tumor cells harboring an overabundance of MET even before treatment can produce longer remissions when treated with combination drugs. This suggests that targeting these cells with additional drugs may be beneficial in preventing resistance.
A study published in BMC Public Health found that childhood traumas are associated with an increased risk of developing lung cancer. The researchers analyzed data from over 17,000 individuals and found that those who experienced six or more traumas were approximately three times more likely to develop lung cancer.
The American Association for Cancer Research and International Association for the Study of Lung Cancer honored Dr. Paul A. Bunn Jr., M.D., for his contributions to lung cancer research. The conference emphasized the importance of translational research in improving lung cancer prognosis.
A new blood test has been developed to aid in lung cancer diagnosis and potentially reduce unnecessary invasive procedures. The test uses a 40-biomarker panel that correctly identified patients with lung cancer 88% of the time and those without it 79% of the time.
A recent study suggests that retreating patients with non-small cell lung cancer who initially responded to gefitinib treatment could lead to additional partial responses and stable disease. The overall disease control rate was 66.7 percent in the retreatment group, offering hope for patients who have failed initial chemotherapy.
A study found that drinking green tea could reduce the risk of lung cancer in smokers, particularly those with specific genetic profiles. Among smokers, those who drank at least one cup of green tea per day had a significantly lower risk of lung cancer compared to non-green tea drinkers.
A 93-gene signature associated with EGFR mutations in tumors from lung cancer patients was found to be a favorable prognostic marker for early stage lung cancer. The signature is also linked to drug sensitivity to erlotinib and gefitinib in non-small cell lung cancer cell lines.
A study found that erlotinib dosing in lung cancer patients depends on their smoking status, with smokers requiring lower doses than non-smokers. Non-smokers were able to tolerate higher doses without developing grade 2 or 3 toxicity, while smokers reached a maximum tolerated dose of 300mg daily.
A new study has found that patients with specific oncogenic rearrangements of the anaplastic lymphoma kinase (ALK) gene in their tumors respond significantly to an ALK-inhibitor therapy. The study suggests a paradigm shift in cancer drug development, allowing for more targeted treatments.
The new T classification is based on tumor size and has been validated as appropriate for pathologic findings. The study found significant differences in survival rates among revised T subsets, highlighting the importance of the revised TMN classification for lung cancer treatment planning.
Researchers at Dana-Farber Cancer Institute have discovered a new compound capable of halting drug-resistant non-small cell lung cancers by targeting a specific protein defect. The pyrimidine WZ4002 has shown promise in restricting cell growth and impeding tumor growth in mice with resistant tumors.
Patients with NSCLC and EGFR mutations showed significantly improved progression-free survival with gefitinib treatment. Gefitinib was also better tolerated than chemotherapy, with fewer severe adverse events.
Researchers found substantial racial and ethnic disparities in cancer survival, particularly in more treatable cancers like breast and prostate cancer. The study suggests that social disadvantage contributes to these disparities, highlighting the need for targeted health policies and interventions.
A study presented at the CTRC-AACR San Antonio Breast Cancer Symposium found that anti-estrogen therapy for breast cancer patients reduced their risk of dying from lung cancer. The research involved 6,715 women diagnosed with breast cancer between 1980 and 2003.
A new mouse model of lung cancer has been developed that replicates the resistance of human lung cancer cells to certain treatments. The study identified secondary mutations in the EGFR gene that contribute to this resistance, which may be targetable with specific drugs.
A diet rich in pistachios may increase dietary intake and serum levels of gamma-tocopherol, potentially reducing lung cancer risk. Pistachio consumption has also been linked to a lower risk of prostate cancer.
Researchers from Yale University and Mirna Therapeutics, Inc., used a naturally occurring tumor suppressor microRNA to reverse the growth of lung tumors in mice. The study found that let-7, a type of micro-RNA, reduced tumors by 66% in mice with non-small cell lung cancer.
A TGen team won a $1,000 prize for their research on identifying microRNAs and imaging features associated with lung cancer metastasis to the brain. The study used microRNAs and imaging characteristics from CT and PET scans as biomarkers to predict brain metastases.
Research analyzed over 100,000 patients with stage IV non-small cell lung cancer and found a modest but statistically significant improvement in one-year and two-year overall survival rates from 13.2% to 19.4% and 4.5% to 7.8%, respectively.
A team of Wistar Institute researchers has identified a 29-gene signature in the blood that can indicate the presence of non-small cell lung cancer at its earliest stages. This discovery could lead to the development of a simple blood test for early-stage lung cancer detection, which would greatly improve treatment outcomes.
New studies show that morphine can boost tumor-cell proliferation and inhibit the immune response, promoting angiogenesis and cancer metastasis. Shielding lung cancer cells from opiates reduces cell proliferation, invasion, and migration in both cell-culture and mouse models.
A new study published in the Journal of the National Cancer Institute found that patient-reported symptoms were more highly associated with day-to-day health status, while clinician reports were more predictive of death and hospitalization. The study suggests that both perspectives are valuable for a comprehensive understanding of trea...
A rapid decline in PET scan activity is correlated with good local tumor control and better lung cancer outcomes. Higher pre-treatment metabolic activity and tumor size are associated with increased risk of death from lung cancer.
A new treatment option has been discovered for patients with early-stage non-small cell lung cancer who are not candidates for surgery. Radical stereotactic radiosurgery performed with CyberKnife leads to a 100% overall survival rate in patients with good lung function, according to a recent study.
A national clinical trial shows that stereotactic body radiation therapy (SBRT) is effective in treating early-stage lung cancer in patients with unrelated medical comorbidities. The primary lung cancer did not recur 98 percent of the time, and more than half of patients were alive three years after diagnosis.
A randomized study found that preventative brain radiation for nonsmall cell lung cancer patients decreased the risk of brain metastases by over 50%, but increased short and long-term memory loss. The study also showed no significant difference in overall survival between treated and untreated patients.
Researchers found that nearly 98% of patients with early-stage non-small cell lung cancer who are unable to undergo surgery experienced no growth of the disease after three years. Additionally, over half of these patients lived for three years after diagnosis, while fewer than 20% experienced a serious decline in health status.
The study found that stereotactic body radiation therapy (SBRT) stopped the growth of lung cancer at its original site for nearly 98% of patients with early non-small cell lung cancer. Researchers also discovered that less than 20% of frail patients experienced a serious decline in health status after treatment.
A study confirmed the efficacy of a simple questionnaire in identifying patients at high risk for lung cancer. The questionnaire, completed by over 1,000 patients, found almost half qualified as high risk and led to eight confirmed cases of lung cancer in five years.
Research finds that lung cancer patients treated in public hospitals are more likely to have advanced stage cancer than those in private hospitals. The study highlights the need for an organized and timely approach to diagnosis and treatment to reduce health care disparities.
Research presented at the ASTRO Annual Meeting has shown that short-term hormone therapy added to radiation increases survival for medium-risk prostate cancer patients, while a shorter radiation course is effective in reducing recurrence rates. Additionally, proton therapy reduces recurrences and is well-tolerated in prostate cancer pa...
Researchers at University Hospitals Case Medical Center found that African Americans with non-small cell lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to EGFR inhibitor drugs. The study highlights the need for personalized treatment approaches based on ethnicity and genetic variation.
A combination of PET/CT tests expedited diagnosis of lung cancer in a fast-tracked setting, demonstrating high sensitivity and accuracy. Researchers evaluated 114 patients and made accurate diagnoses for 92%, with malignancy detected in 84%. This approach allows for timely treatment initiation without delays.
Research links CHRNA3 and CHRNA5 genes to increased lung cancer risk in African Americans, despite lower smoking rates. The study, published in Journal of Thoracic Oncology, confirms a stronger association with lung cancer risk than nicotine dependence.
A recent study confirms radon gas is the second leading cause of lung cancer, after smoking, in Spain and Romania. Radon levels were found to be a significant risk factor for lung cancer in homes, particularly in granite areas.
A University of Toronto-led nanomedicine research group has received a $5-million grant to develop technologies that allow for more selective detection of diseases, including lung and leukemia cancers. The team aims to speed up cancer diagnosis by incorporating plasmonics into existing procedures.
New research finds that adding cetuximab to chemotherapy reduces the risk of death from advanced non-small cell lung cancer by 13%, while also slowing disease progression and increasing the chance of tumor shrinkage. The study, which included over 2,000 patients, also found a 10% improvement in progression-free survival.
A randomized phase III study found that pemetrexed significantly improved progression-free survival (4.3 months vs 2.6 months) and overall survival (13.4 months vs 10.6 months) compared to placebo in patients with advanced non-squamous NSCLC who did not progress after initial platinum-based chemotherapy.
A large trial found that hormone replacement therapy (HRT) increases the risk of death from lung cancer, especially non-small-cell lung cancer. Women taking HRT were 71% more likely to die from lung cancer than those on placebo, with higher risks also seen in current and long-term past smokers.
Researchers at Johns Hopkins Medicine have identified unique characteristics of lung cancer in never-smokers, including exposure to second-hand smoke and radon gas. The guide recommends specific treatments, such as EGFR inhibitors, for patients with genetic mutations.
The report finds Hispanic/Latino Americans have a unique cancer risk profile, with lower incidence rates for all cancers combined, but higher rates of stomach, cervix, liver, and gallbladder cancers. They also experience later stage diagnoses for many cancers, including breast and melanoma.
Researchers found that primary lung cancer shifts to metastatic disease by suppressing microRNA-200, a family of small molecules that normally locks the tumor in a noninvasive state. Protecting miR-200 from blockade completely prevented metastasis in mice.
Researchers at the Mayo Clinic have discovered that the lung cancer oncogene PKCiota is necessary for the proliferation of lung cancer stem cells. The study found that an agent called aurothiomalate substantially inhibits growth of these cancer stem cells, suggesting a potential new treatment target.
Research published in the Journal of Thoracic Oncology found that narrow-band imaging bronchoscopy increases lung cancer detection specificity and can serve as an alternative method. The study confirms its efficiency by comparing it with white light and auto-fluorescence imaging.
A pooled analysis of six clinical trials found that pretreatment quality of life can predict overall survival in patients with advanced stage NSCLC. Patients with low self-assessed quality of life have twice the risk of death as those with high scores.
Researchers developed a gene assay that identifies key genes contributing to drug resistance in non-small cell lung cancer. The assay showed strong correlation between multi-gene signatures and individual chemotherapy agents, allowing for personalized treatment guidance.
The Tobacco Atlas estimates that tobacco use kills six million people annually, with two million cancer deaths projected by 2015. The global economy loses $500 billion due to tobacco use, mainly in low- and middle-income countries.
A recent study published in the Journal of Thoracic Oncology found that tumor size and level of visceral pleura invasion significantly impact the survival of non-small cell lung cancer (NSCLC) patients. Researchers analyzed data from over 9,700 surgical resection cases and divided patients into nine groups based on tumor size and VPI.
Researchers at the University of Pittsburgh School of Medicine have discovered a protein called cyclin B1 that is made in excess levels in many cancers. A vaccine targeting this protein may prevent malignancies in high-risk individuals, with promising results in mice vaccinated against it. The study's findings suggest that natural immu...
Researchers found that combination therapies tailored to patient prognosis improved patient outcomes and increased five-year, disease-free survival rates. Prophylactic cranial irradiation was shown to significantly decrease the risk for brain metastases in NSCLC patients.
A Montreal study links heavy consumption of beer and spirits to an increased risk of six different cancers, including oesophageal, colon, lung, pancreatic, liver, and prostate cancer. Heavy drinkers face a sevenfold increased risk of esophageal cancer and an 80% higher risk of colon cancer.
Researchers found that patients with second primary lung cancers (SPLC) are more likely to receive surgical treatment and have localized disease at diagnosis compared to those with one primary lung cancer (OPLC). However, SPLC patients experience a 12% higher lung cancer-specific mortality rate.
Studies presented at the WCLC confirm that targeted therapies have improved efficacy and prolonged progression-free survival time compared to chemotherapy. Patients with EGFR mutations who received gefitinib experienced longer progression-free survival and greater objective response rates, while erlotinib showed prolonged progression-f...
A combination of bevacizumab and erlotinib appears to be effective in treating non-small cell lung cancer (NSCLC) in elderly patients, with four partial responses observed. The regimen is well-tolerated, with common side effects including high blood pressure, fatigue, and diarrhea.
Researchers at Fox Chase Cancer Center have found that lung cancer patients who have progressed on a cetuximab-containing regimen may respond to erlotinib. The study suggests that patients who are no longer controlled by cetuximab can derive clinical benefit from erlotinib, offering an additional treatment option.
Fox Chase researchers found that DLX5 promotes cancer by activating the expression of MYC, a potent factor in numerous cancers. The discovery suggests that DLX5 could be an ideal target for future anti-cancer drugs.